Osteoporosis in patients with inflammatory bowel disease.

Compston, Juliet; Judd, D; Crawley, E.O.; Evans, W. D.; Evans, Carol; Church, Hannah; Reid, E M; Rhodes, J.

doi:10.1136/gut.28.4.410

Cited by 287 publications

(108 citation statements)

References 26 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…One predictive factor was the BMI. This relationship has been described in several previous studies [17, 18,35,36,37], and follow-up studies with repeated BMD measurements have shown that a reduction in BMI leads to bone loss [20, 38]. Furthermore, young age was identified as a predictive variable for both low Z and T scores, although the regression coefficients were low (0.020 and 0.025 for femoral and lumbar Z scores, respectively).…”

Section: Discussionmentioning

confidence: 80%

Analysis of Risk Factors for Low Bone Mineral Density in Inflammatory Bowel Disease

et al. 2006

View full text Add to dashboard Cite

Background/Aim: Several risk factors have been suggested for osteoporosis which frequently occurs in inflammatory bowel disease (IBD) patients. We studied prevalence and risk factors for reduced bone mineral density (BMD) in IBD patients at the University Hospital of Zürich, Switzerland. Methods: The BMD was determined by dual-energy X-ray absorptiometry at the lumbar spine and femoral neck in 88 IBD patients (55 with Crohn’s disease, 30 with ulcerative colitis, and 3 with indeterminate colitis). Z scores were obtained by comparison with age- and sex-matched normal values, and T scores by comparison with sex-matched healthy young adults. Osteopenia and osteoporosis were defined according to the WHO guidelines. Predictive factors for BMD were analyzed by group comparison and stepwise regression analysis. Results: Osteopenia was present in 43% of the patients at the lumbar spine and in 42% of them at the femoral neck. Osteoporosis was present in 14% of the patients at the lumbar spine and in 5% of them at the femoral neck. At the lumbar spine, stepwise regression analysis showed that body mass index, age, number of bowel resections, topic steroids, and azathioprine correlated with the Z scores. Cumulative steroid dose, topic steroids, age and bowel resection were found to be predictors for a pathological T score. At the femoral neck, regression analysis showed that body mass index, age, topic steroids, and azathioprine correlated with the Z scores. Only a low body mass index was a significant predictor for pathological femoral T scores. Conclusions: Osteopenia and osteoporosis are commonly found in IBD patients. Steroid treatment and bowel resection were significant risk factors for osteoporosis of the lumbar spine. However, disease-inherent factors also appear to confer a major risk, indicating that the BMD should be determined in all IBD patients, irrespective of steroid treatment.

show abstract

Section: Discussionmentioning

confidence: 80%

Analysis of Risk Factors for Low Bone Mineral Density in Inflammatory Bowel Disease

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Decreased bone mineral density (BMD) has been reported in 31% to 59% of patients with IBD (2)(3)(4)(5)(6)(7)(8)(9). The mechanism of bone loss in IBD is likely to be multifactorial.…”

mentioning

confidence: 99%

Risk of Osteopenia after Proctocolectomy and Ileal Pouch-Anal Anastomosis for Ulcerative Colitis

Kuisma¹,

Luukkonen²,

Järvinen³

et al. 2002

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Metabolic bone disease is an established complication in patients with infl ammatory bowel disease (IBD) occurring in as many as 30-77% of patients [1,2] . It is more common in Crohn's disease (CD) than in ulcerative colitis (UC) [3] .…”

Section: Introductionmentioning

confidence: 99%

Infliximab Therapy Improves the Bone Metabolism in Fistulizing Crohn’s Disease

Miheller

Műzes

Zágoni

et al. 2006

Dig Dis

View full text Add to dashboard Cite

Background: Tumor necrosis factor-α (TNF-α) plays a pivotal role in the pathogenesis of inflammatory bowel diseases and bone resorption as well. Limited data exist about the effect of anti-TNF-α infliximab on bone metabolism in inflammatory-type Crohn’s disease (CD). Aim: Our aim was to evaluate the effect of infliximab treatment on rapid changes of bone metabolism in fistulizing CD patients. Methods: 27 patients with fistulizing CD were treated with three series of infliximab. Serum osteocalcin (OC) and β-CrossLaps (bCL) were measured before administration of each infliximab infusion. 54 patients with inactive CD were controls. Results: In treated patients, there were significant differences in bCL concentrations on days 0 and 14 (p < 0.01) and days 0 and 42 (p < 0.05). OC levels increased significantly between day 0 and 42 (p < 0.05). The values of bCL and OC of control groups differed from serum levels in active patients before the treatment, but not on day 42. Bone markers improved significantly in responder patients, but not in non-responders. Conclusion: The beneficial effect of infliximab to the bone metabolism is more expressive in patients whose fistulizing disease improves with this therapy. Our results suggest that TNF-α has an important role in the alteration of bone metabolism in fistulizing CD patients.

show abstract

Osteoporosis in patients with inflammatory bowel disease.

Cited by 287 publications

References 26 publications

Analysis of Risk Factors for Low Bone Mineral Density in Inflammatory Bowel Disease

Analysis of Risk Factors for Low Bone Mineral Density in Inflammatory Bowel Disease

Risk of Osteopenia after Proctocolectomy and Ileal Pouch-Anal Anastomosis for Ulcerative Colitis

Infliximab Therapy Improves the Bone Metabolism in Fistulizing Crohn’s Disease

Contact Info

Product

Resources

About